(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 152.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Tonix Pharmaceuticals Holding's revenue in 2025 is $9,831,000.On average, 2 Wall Street analysts forecast TNXP's revenue for 2025 to be $84,152,602, with the lowest TNXP revenue forecast at $76,263,295, and the highest TNXP revenue forecast at $92,041,908. On average, 2 Wall Street analysts forecast TNXP's revenue for 2026 to be $1,029,116,190, with the lowest TNXP revenue forecast at $274,372,545, and the highest TNXP revenue forecast at $1,783,859,836.
In 2027, TNXP is forecast to generate $1,152,715,324 in revenue, with the lowest revenue forecast at $1,152,715,324 and the highest revenue forecast at $1,152,715,324.